Core B - David ElderThe Pathology Core is responsible for the provision of expert pathological assistance in the interpretation ofhistological data to the Projects, for the development of immunohistochemical and in situ hybridizationmethods to enable the identification of antigens or mRNAs in archival and freshly-isolated tissues, and foraccrual of residual material not required for diagnosis from human melanomas and nevi for use in theProjects. Expertise in all aspects of the pathological diagnosis and classification of melanocytic neoplasms isprovided to the projects on a continuing basis, and is useful in the characterization of experimental models,as well as in the evaluation of expression of novel and experimental markers in benign, intermediate, andmalignant melanocytic tumors. The Core personnel are expert in standard immunohistochemical and in situhybridization techniques, and are very experienced in the workup of novel antibodies and probes. Underprevious funding, the Core has been continuously involved in the procurement, prioritization, and provision oftissue, blood, and other biological samples for research projects. Appropriate IRB approved informedconsent protocols are used. The Core maintains a shared bank of frozen tissue, and of paraffin blocksand/or sections, from melanocytic tumors, The Core has participated in the production of two tissuemicroarrays with cooperative groups and has access to slides from these. In addition, the Core is involved inan ongoing basis in the continuing accrual of tissues. These functions are shared with other programs,providing efficiencies that allow this Core to provide a much wider arrange of services and procurementfunctions than might otherwise be feasible. Biosamples are prioritized through a Tissue AllocationCommittee that includes investigators from this program project, as well as from other programs. In thismanner, collection, initial processing, storage if necessary, prioritization, distribution, and usage of material inthe projects can be reliably tracked and optimized to ensure the best use of scarce tissue resources.
| Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268 |
| Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215 |
| Emptage, Ryan P; Lemmon, Mark A; Ferguson, Kathryn M et al. (2018) Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain. Structure 26:1137-1143.e3 |
| Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705 |
| Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426 |
| Pathria, Gaurav; Scott, David A; Feng, Yongmei et al. (2018) Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J 37: |
| Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072 |
| Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov : |
| Kaur, Amanpreet; Ecker, Brett L; Douglass, Stephen M et al. (2018) Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov : |
| Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386 |
Showing the most recent 10 out of 144 publications
